Welcome to the Desert Angels™. We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies. The organization serves as a forum for its over 90 members, who invest individually from their personal funds. Since 2000, Desert Angel members have invested over $37 million in more than 85 presenting companies.

SalutarisMD Honored with AZBio Fast Lane Award As It Ramps Up for Commercialization of Sight-saving Treatment

by Curtis Gunn on September 19th, 2016 at 5:28pm

As it prepares for its commercial product launch in Europe and new clinical studies in the United States, SalutarisMD® (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) will be in the spotlight at the 2016 AZBio Awards on September 21, 2016 as they are honored with the AZBio Fast Lane Award.

The following day, on September 22, 2016, Dr. Laurence Marsteller, SalutarisMD® CEO will provide further updates to investors from across the United States at the White Hat Life Science Investor Conference.

Read full article here

Comment

Filed under: Uncategorized

Tempronics Successfully Closes $9.5M Series C Round

by Curtis Gunn on September 13th, 2016 at 4:36pm

Lear Corporation Leads Round and Enters into a Strategic Partnership to Bring a New Generation of Heating and Cooling Technology to the Automotive Market

Tempronics, a thermoelectric company with proprietary new technology in solid state heating and cooling, is partnering with the Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, to provide a new generation of thermal comfort to the automotive seating market. Other investors include Nth Power, the Desert Angels, management and individual investors.

Read full article here

Comment

Lear Enters into a Strategic Partnership with Tempronics and Secures Exclusive Rights to Thermoelectric Seat Heating and Cooling Technology for use in Automotive Applications

by Curtis Gunn on September 8th, 2016 at 4:26pm

Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, today announced that it has entered into a strategic partnership with Tempronics, pursuant to which Lear obtained a minority equity interest in Tempronics and also secured exclusive rights to its thermoelectric seat heating and cooling technology for automotive applications.

“This partnership will provide Lear with the ability to heat and cool seats faster utilizing less energy than any other system available today,” said Ray Scott, Lear’s executive vice president and president of Seating.

Read full article here

Comment

Beacon Biomedical Inc. Honored with AZBio Fast Lane Award as It Ramps up for Commercialization

by Curtis Gunn on September 8th, 2016 at 4:12pm

Beacon Biomedical’s progress towards its commercial product launch this fall will be in the spotlight at the 2016 AZBio Awards on September 21, 2016 as they are honored with the AZBio Fast Lane Award.

If early detection saves lives, then why, with all the billions of dollars being spent on patient education and awareness as to the life-saving benefits of routine cancer screening, are we seeing hundreds of thousands of people still dying each year from cancer? That question was the genesis behind Beacon Biomedical.

Read full article here

Comment

Filed under: News Releases, Press

FDA Allows NuvOx Pharma’s IND to Initiate Phase Ib Clinical Trial in Stroke.

by Curtis Gunn on August 19th, 2016 at 5:06pm

Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.

The trial will be performed at the University of Arkansas Medical System in Little Rock, Arkansas under the direction of Dr. William Culp, Jonathan Fitch Distinguished Chair in Stroke. Dr. Culp said, “We have studied NVX-208 in a number of pre-clinical stroke models and found that administration of NVX-208 decreases the brain damage from stroke by over 80%. The only approved drug to treat stroke is t-PA, which has a risk of bleeding and is approved for use only up to 3 hours following stroke. Administration of NVX-208 prior to t-PA extended the time window of efficacy to at least 9-hours. NVX-208 has great potential to allow many more stroke patients to be treated and to improve their outcomes. This trial will determine the recommended dose of NVX-208 in stroke patients so that it can be subsequently tested in a randomized study in stroke patients.”

Read full article here

Comment

Filed under: Funded Companies, Press

PR Product Recommendation: IrisPR Software

by Curtis Gunn on August 11th, 2016 at 5:05pm

We recently started using the new PR performance software tool IrisPR and we are loving it!

You can tell IrisPR is a tool created by PR professionals. With it, you can capture the names of your media contacts, gather the clips of the coverage you generate, and track the status of your PR campaigns and pitches! It’s as if your media database merged with your media monitoring service and all those spreadsheets of PR results that you’ve had to create yourself!

Read full article here

Comment

Filed under: Funded Companies, Press

Calimmune CEO Louis Breton Named to PharmaVOICE 100 for 2016

by Curtis Gunn on August 10th, 2016 at 3:34pm

Calimmune, Inc., a clinical-stage gene therapy company, is pleased to announce that its Chief Executive Officer, Louis Breton, has been selected by PharmaVOICE magazine as one of the top 100 most inspirational and extraordinary leaders in the life sciences industry for 2016.

Read full article here

Comment

Filed under: Uncategorized

Playability Toys Nurture Smart Mobile Named Finalist for 2016 IDSA International Design Excellence Award

by Curtis Gunn on July 26th, 2016 at 4:50pm

Playability Toys, a leading maker of therapeutic toys and apps that enhance and improve the lives of children and their families, today announced that its Nurture Smart Mobile is an Industrial Designers Society of America’s (IDSA) 2016 International Design Excellence Award (IDEA) finalist in the Children’s Products category. The first and only clinical grade mobile of its kind, the Nurture Smart Mobile was judged by renowned design experts around the world among a field of more than 1,700 designs projects from 30-plus countries.

Read full article here

Comment

Filed under: Uncategorized

HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis

by Curtis Gunn on July 19th, 2016 at 1:37pm

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).

Read full article here

Comment

Filed under: Uncategorized

HTG Molecular Diagnostics Announces VERI/O Laboratory Service

by Curtis Gunn on June 27th, 2016 at 5:18pm

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development.

The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.

Read full article here

Comment

Filed under: Uncategorized